Work Here?
Cerevel Therapeutics
Work Here?
Clinical-stage biopharma developing CNS therapies
Cerevel Therapeutics
Work Here?
Clinical-stage biopharma developing CNS therapies
Overview
Cerevel Therapeutics develops new therapies for neuroscience diseases, focusing on conditions like Parkinson’s, epilepsy, and schizophrenia. It combines advanced chemistry with CNS receptor pharmacology to create drug candidates that target brain receptors and neurocircuitry, and advances them through clinical trials to test safety and efficacy. The company differentiates itself through a biology-driven approach grounded in brain biology and neurocircuitry, supported by partnerships with Pfizer and Bain Capital, to pursue targeted CNS drug discovery. Its goal is to deliver rigorously evaluated treatments that improve outcomes for patients worldwide by expanding the possibilities in neuroscience.
About Cerevel Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2018
Simplify's Take
What believers are saying
- Tavapadon Phase III TEMPO-3 showed 1.1-hour clinically meaningful treatment effect.
- AbbVie's $8.7B acquisition provides substantial R&D funding and commercialization resources.
- Multiple clinical-stage programs address high-unmet-need neuropsychiatric and neurodegenerative conditions.
What critics are saying
- Emraclidine failed Phase II schizophrenia trials versus placebo, destroying lead asset value.
- Karuna's KarXT M4 agonist gained FDA approval, capturing schizophrenia market first.
- AbbVie may terminate early-stage Cerevel programs post-emraclidine failure to cut costs.
What makes Cerevel Therapeutics unique
- First-in-class D1/D5 dopamine partial agonist targeting Parkinson's motor pathways specifically.
- Neurocircuitry expertise combined with receptor subtype selectivity across CNS disorders.
- Diversified pipeline spanning schizophrenia, Parkinson's, epilepsy, panic disorder, depression.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$10.5B
Above
Industry Average
Funded Over
8 Rounds
Stock Price
Company News
AbbVie's experimental schizophrenia drug, emraclidine, acquired through a $9 billion purchase of Cerevel Therapeutics, failed to show significant patient improvement in Phase 2 trials using the PANSS test compared to a placebo. AbbVie's chief scientific officer, Roopal Thakkar, expressed disappointment and stated that the company is analyzing the data to determine next steps.
AbbVie has completed the acquisition of Cerevel Therapeutics, a company with a portfolio of neurological and psychiatric products. AbbVie acquired all outstanding shares of Cerevel for $45 (€40.47) each. Cerevel's shares ceased trading on NASDAQ on August 1, 2024. AbbVie expects the acquisition to increase earnings per share starting in 2030.
Cerevel, meanwhile, was acquired by AbbVie for $8.7 billion.
AbbVie has completed its acquisition of Cerevel Therapeutics for approximately $8.7 billion-strengthening its foundation in neuroscience and positioning itself to deliver sustainable long-term performance.
AbbVie's acquisition of Cerevel Therapeutics for nearly $9 billion, announced in December 2023, is expected to close soon, potentially as early as next week, despite an FTC "second request" for additional information in February. AbbVie CEO Rob Michael confirmed substantial compliance with the FTC's request and no expected divestments. Cerevel will become a subsidiary of AbbVie, enhancing its neuroscience franchise. Cerevel’s stock rose 2.4%, and AbbVie’s rose 3.4% post-announcement.
There are no jobs for Cerevel Therapeutics right now.
Find jobs on Simplify and start your career today
About Cerevel Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2018
There are no jobs for Cerevel Therapeutics right now.
Find jobs on Simplify and start your career today